Through the SynergiQc program, the Canadian Cancer Society (CCS), the Cole Foundation (and collaborating donors), Oncopole – Pôle cancer du FRQS (Oncopole ) and CQDM join forces to support collaborative translational research and development (R&D) projects on pediatric and young adult cancers, in particular leukemia and lymphoma. This partnership creates a unique funding mechanism to bring together experts from academia and industry to support the development of biopharmaceutical platforms, tools and products that will pave the way for new advances in the prevention, diagnosis and treatment of pediatric cancers.

Thanks to this new partnership, researchers in Quebec’s public networks conducting translational research in pediatric oncology could obtain funding of up to 90% of the value of their project (for projects of up to $2 million). The research team must include at least one biotechnology or pharmaceutical company with R&D or manufacturing operations in Quebec, which must commit to making a minimum contribution of 10%.

Consult program rules

Objectives

• Increase research collaborations and partnerships between universities and companies in Quebec’s life sciences ecosystem to improve treatments for pediatric and young adult cancers;
• Enable technological maturation and industrial value creation to generate economic spin-offs for project stakeholders and for Quebec;
• Contribute to the valorization of knowledge, know-how and new technologies developed in public institutions and their transfer to industry.

Total competition budget: $5,000,000

Amount awarded per project : minimum $500,000 maximum $2,000,000

Important dates

• Deadline for notice of interest: December 1, 2021
• Application deadline: December 8, 2021

For further information, please contact the following people:

• Oncopole: Maxime Dumais, Development Coordinator – Oncopole.
• SynergiQc Program: Véronique Dugas, Vice-President, Scientific Affairs, CQDM